中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.015 seconds)

    ANTIBODIES DIRECTED AGAINST HLA-B27 HOMODIMERS AND METHODS AND USES THEREOF IN DIAGNOSIS AND THERAPY
    1.
    发明申请
    ANTIBODIES DIRECTED AGAINST HLA-B27 HOMODIMERS AND METHODS AND USES THEREOF IN DIAGNOSIS AND THERAPY 审中-公开
    针对HLA-B27抗体的抗体及其在诊断和治疗中的用途及其用途

    公开(公告)号：WO2012047294A3

    公开(公告)日：2012-06-21

    申请号：PCT/US2011001722

    申请日：2011-10-06

    Applicant: LUDWIG INST FOR CANCER RES LTD ,  UNIV ZUERICH ,  CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD ,  RENNER CHRISTOPH ,  WADLE ANDREAS ,  PAYELI SRAVAN ,  THIEL MARKUS ,  BOWNESS PAUL ,  KOLLNBERGER SIMON

    Inventor： RENNER CHRISTOPH ,  WADLE ANDREAS ,  PAYELI SRAVAN ,  THIEL MARKUS ,  BOWNESS PAUL ,  KOLLNBERGER SIMON

    IPC: A61K39/395 ,  C07K16/00 ,  C12P21/08

    CPC classification number: C07K16/28 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to HLA-B27 heavy-chain homodimers, termed HC-B27, HLA-B272 or B272, particularly recognizing B272 homodimers and which do not recognize or bind HLA-B27 heterotrimers (B27) including HLA-B27 heterotrimers with ß2 microglobulin and peptide. These antibodies are useful in the diagnosis and treatment of HLA-B27 mediated conditions, particularly those associated with B272, the spondylarthritides, a group of related diseases including ankylosing spondylitis (AS) and reactive arthritis (ReA or Reiter's syndrome). The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the present invention may also be used in therapy in combination with chemotherapeutics, immune modulators, anti-inflammatory drugs, NSAIDs and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies HD4, HD5 and HD6 whose sequences are provided herein.

    Abstract translation: 特异性结合成员，特别是抗体及其片段，其结合HLA-B27重链同源二聚体，称为HC-B27，HLA-B272或B272，特别是识别B272同型二聚体并且不识别或结合HLA-B27异源三聚体（B27） 包括具有β2微球蛋白和肽的HLA-B27异源二聚体。 这些抗体可用于诊断和治疗HLA-B27介导的病症，特别是与B272相关的那些，脊椎关节炎，一组相关疾病，包括强直性脊柱炎（AS）和反应性关节炎（ReA或Reiter综合征））。 本发明的抗体，可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂，抗炎药物，NSAIDs和/或与其它抗体或其片段组合的治疗中。 这种抗体的例子是本文提供其序列的新型抗体HD4，HD5和HD6。

    TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
    2.
    发明申请
    TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF 审中-公开
    TGF-β3特异性抗体及其用途及其用途

    公开(公告)号：WO2016201282A3

    公开(公告)日：2017-01-19

    申请号：PCT/US2016036965

    申请日：2016-06-10

    Applicant: LUDWIG INST FOR CANCER RES LTD

    Inventor： VAN SNICK JACQUES ,  UYTTENHOVE CATHERINE

    IPC: C07K16/00 ,  C07K16/22 ,  C12Q1/68

    CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/73 ,  C07K2317/76

    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

    Abstract translation: 提供了结合转化生长因子β3（TGF-β3）的特异性结合成员，特别是其抗体及其片段，特别是识别人和小鼠TGF-β3，特别是不识别或结合TGF-β1或TGFβ的抗体和片段 -β2。 提供特异性识别和中和TGF-β3的特异性抗体。 这些抗体可用于诊断和治疗与活化或升高的TGF-β3（包括癌症）相关的病症，以及用于调节免疫细胞和免疫应答，包括对癌症或癌症抗原的免疫应答。 抗TGF-β3抗体，其可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。 这种抗体以本发明的抗体为例，包括本文提供的序列的抗体MTGF-β3-9，MTGF-β3-12，MTGF-β3-16，MTGF-β3-17和MTGF-β3-19。

    REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE
    4.
    发明申请
    REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE 审中-公开
    可逆蛋白多聚体，其生产和使用方法

    公开(公告)号：WO2012044999A3

    公开(公告)日：2012-06-07

    申请号：PCT/US2011054335

    申请日：2011-09-30

    Applicant: LUDWIG INST FOR CANCER RES LTD ,  LUESCHER IMMANUEL F ,  SCHMIDT JULIEN ,  GUILLAUME PHILIPPE ,  DOJCINOVIC DANIJEL

    Inventor： LUESCHER IMMANUEL F ,  SCHMIDT JULIEN ,  GUILLAUME PHILIPPE ,  DOJCINOVIC DANIJEL

    IPC: C07K1/04

    CPC classification number: C07K17/00 ,  A61K39/00 ,  A61K39/385 ,  A61K2039/605 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/70539

    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor- mediated T-cell activation can be minimized. The use of reversible MHC multimers as provided herein, accordingly, allows for the detection and isolation of bona fide antigen- specific CD8+ T cells without inducing activation dependent cell death, including rare, therapeutically valuable T- cells expressing T-cell receptors binding tumor antigens with high affinity. Methods for the production and use of reversible multimers are also provided.

    Abstract translation: 本发明的一些方面基于这样的认识：其中单体蛋白通过螯合复合键与载体分子缀合的可逆蛋白多聚体在生理条件下是稳定的，并且可以在生理，无毒条件下以受控的方式解离。 因此，这种蛋白质多聚体可用于各种体外，离体和体内应用于研究，诊断和治疗。 本发明的一些方面提供可逆的MHC蛋白多聚体，以及在检测和/或分离特异性T细胞或T细胞群体中使用这种多聚体的方法。 由于可逆的MHC多聚体可以有效解离，可以将MHC与T细胞受体结合的时间以及T细胞受体介导的T细胞活化降至最低。 因此，本文提供的可逆MHC多聚体的使用允许真正的抗原特异性CD8 + T细胞的检测和分离，而不诱导活化依赖性细胞死亡，包括表达结合肿瘤抗原的T细胞受体的罕见的，治疗有价值的T细胞 具有高亲和力。 还提供了生产和使用可逆多聚体的方法。

    TNF-IMMUNOCONJUGATES WITH FIBROBLAST ACTIVATION PROTEIN ANTIBODIES AND METHODS AND USES THEREOF
    5.
    发明申请
    TNF-IMMUNOCONJUGATES WITH FIBROBLAST ACTIVATION PROTEIN ANTIBODIES AND METHODS AND USES THEREOF 审中-公开
    具有纤维蛋白激活蛋白抗体的TNF-免疫球蛋白及其方法及用途

    公开(公告)号：WO2011040973A3

    公开(公告)日：2011-11-24

    申请号：PCT/US2010002661

    申请日：2010-10-01

    Applicant: LUDWIG INST FOR CANCER RES LTD ,  BAUER STEFAN ,  WUEST THOMAS ,  RENNER CHRISTOPH

    Inventor： BAUER STEFAN ,  WUEST THOMAS ,  RENNER CHRISTOPH

    IPC: A61K47/48 ,  A61P35/00

    CPC classification number: B82Y5/00 ,  A61K47/646 ,  A61K47/66

    Abstract: Protein-immunoco?jugates are provided, particularly TNF conjugates to antibodies and fragments thereof which bind to Fibroblast Activation Protein (FAP). TNF-FAP antibody conjugates are provided wherein the FAP antibody recognizes both human and mouse FAP. These immunoconjugates are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis, and more broadly in TNF responsive conditions and disorders, including cancer and hyperproliferative diseases. In addition, the FAP-immunoconjugates can be used for the diagnosis and treatment of FAP positive tumors such as pancreatic cancer, melanoma and sarcomas. The immunoconjugates, antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the present invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.

    Abstract translation: 提供蛋白质免疫缺陷蛋白，特别是与结合成纤维细胞活化蛋白（FAP）的抗体及其片段的TNF缀合物。 提供TNF-FAP抗体缀合物，其中FAP抗体识别人和小鼠FAP。 这些免疫缀合物可用于诊断和治疗与活化基质相关的病症，包括伤口愈合，上皮癌，骨关节炎，类风湿性关节炎，肝硬化和肺纤维化，更广泛地涉及TNF反应性病症和疾病，包括癌症和过度增生性疾病。 此外，FAP-免疫缀合物可用于诊断和治疗FAP阳性肿瘤如胰腺癌，黑素瘤和肉瘤。 本发明的免疫缀合物，抗体，可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

Patent Agency Ranking